Citi Upgrades Merus N.V. (MRUS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Merus (MRUS) PT Doubled to $32 at Wedbush Amid Incyte Deal
December 21, 2016 11:50 AM ESTWedbush analyst David Nierengarten raised his price target on Outperform-rated Merus N.V. (NASDAQ: MRUS) to $32.00 (from $16.00) after the company and Incyte announced a collaboration to develop up to eleven bispecific antibody research programs using MRUSs Biclonics platform, including two of MRUSs current preclinical... More
Merus N.V. (MRUS) Surges 50% on Incyte (INCY) Collaboration
December 21, 2016 8:15 AM ESTMerus N.V. (NASDAQ: MRUS) surges 51% in pre-open trade after the company and Incyte Corporation (NASDAQ: INCY) entered into a global,... More
Merus N.V. (MRUS) and Incyte (INCY) Announce Research Collaboration
December 21, 2016 7:02 AM ESTIncyte Corporation (NASDAQ: INCY) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and development of bispecific antibodies utilizing Merus proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus current preclinical immuno-oncology discovery programs.
Biclonics® retain the IgG format of antibodies that are produced naturally by the immune system and, by binding to two targets, enable multiple modes of... More
